|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Dabigatran** | **Apixaban** | **Edoxaban** | **Rivaroxaban** |
| **Bioavailability** | 3-7% | 50% | 62% | 15 mg/20 mg: 66% without food, 80–100% with food |
| **Prodrug** | Yes | No | No | No |
| **Clearance non-renal/renal of absorbed dose** | 20%/80% | 73%/27% | 50%/50% | 65%/35% |
| **Plasma protein binding** | 35% | 87% | 55% | 95% |
| **Dialysability** | 50-60% | 14%(in part dialysable) | n.a.(in part dialysable) | n.a.(in part dialysable) |
| **Liver metabolism: CYP3A4 involved** | No | Yes [elimination, moderate contribution (􏰄25%)a] | Minimal (<4% of elimination) | Yes (hepatic elimination 18%) |
| **Absorption with food** | No effect | No effect | 6-22% more; minimal effect on exposure | 39% more (see above) |
| **Absorption with H2B/PPI** | -12% to 30% (not clinically relevant) | No effect | No effect | No effect |
| **Asian ethnicity** | +25% | No effect | No effect | No effect |
| **Elimination half-life** | 12–17 h | 12 h | 10–14 h | 5–9 h (young)11–13 h (elderly) |
| **Other** | Dyspepsia (5–10% |  |  | Intake of 15 mg/20 mg with food mandatory |

**Table 3:** Absorption and metabolism of the different DOACs. Adapted from Steffel *et al,* European Heart Journal (3).